Wessels B W, Rogus R D
Med Phys. 1984 Sep-Oct;11(5):638-45. doi: 10.1118/1.595559.
An absorbed dose calculation comparison has been computed for radiolabeled tumor associated antibodies distributed over a standard geometry and tumor location. Half-life data, maximum specific activities, and relative organ doses of nine radionuclides, Cu-67, Br-77, Br-82, Y-90, Tc-99m, In-111, I-131, Re-186, and At-211, have been compiled in which the radionuclides were assumed to be coupled with antibody. These nuclides were chosen on the basis of physical characteristics that warranted their inclusion as either imaging or therapy radiolabels. Radionuclide biodistribution data based on current available estimates for antibody uptake and clearance in humans has been adopted. Re-186 and Y-90 have been determined to be among the best therapy radiolabels since they possess sufficiently long half lives necessary for tumor localization, little or no gamma radiation, intermediate beta energy, stable daughter products, and have a reasonable chance to form a stable chelate with an antibody system.
已针对分布在标准几何形状和肿瘤位置上的放射性标记肿瘤相关抗体进行了吸收剂量计算比较。已汇编了九种放射性核素（铜 - 67、溴 - 77、溴 - 82、钇 - 90、锝 - 99m、铟 - 111、碘 - 131、铼 - 186和砹 - 211）的半衰期数据、最大比活度和相对器官剂量，其中假设这些放射性核素与抗体偶联。选择这些核素是基于其物理特性，这些特性使其有资格作为成像或治疗放射性标记。已采用基于目前人类抗体摄取和清除可用估计值的放射性核素生物分布数据。铼 - 186和钇 - 90已被确定为最佳治疗放射性标记之一，因为它们具有肿瘤定位所需的足够长的半衰期、很少或没有伽马辐射、中等β能量、稳定的子产物，并且有合理的机会与抗体系统形成稳定的螯合物。
